Rituxan deaths reported to FDA

Share this article:
The deaths of two women being treated with Genentech's Rituxan (rituximab) for systemic lupus erythematosus have been reported to the FDA. The agency is working with the company to obtain additional info and to strengthen the warnings in the product labeling.

Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.